^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mocaciclib (Q901)

    i
    Other names: Q901, Q 901, Q-901
    Company:
    Lead Discovery Center, Qurient
    Drug class:
    CDK7 inhibitor
    Related drugs:
    over2years
    Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Qurient Co., Ltd. | N=70 --> 130
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • mocaciclib (Q901)
    over2years
    Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor (AACR 2023)
    The non-clinical data demonstrate that Q901 not only has a potential as a single agent,but can also be used in combination with other therapeutic strategies to develop next-generation cancer therapeutics to potentially address unmet medical needs.
    Clinical • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • BRCA (Breast cancer early onset)
    |
    ER positive • HR positive • BRCA wild-type
    |
    mocaciclib (Q901)
    3years
    Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    mocaciclib (Q901)
    over3years
    Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Qurient Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    mocaciclib (Q901)